Expanding Options for Emerging Biopharma in the U.S.
Expanding Options for Emerging Biopharma in the U.S.
66 PagesThis report examines the evolving landscape of evidence-based pricing (EBP) in the U.S. as healthcare systems seek to balance innovation, affordability, and patient access. It outlines current EBP models, including outcomes-based contracts and indication-specific pricing, and evaluates barriers such as data infrastructure gaps, regulatory complexity, and misaligned incentives. The analysis highlights opportunities to expand EBP through better real-world data, standardized metrics, and collaboration between manufacturers, payers, and providers to improve value assessment and reimbursement decisions.
